These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 39271288)
21. The biology of lantibiotics from the lacticin 481 group is coming of age. Dufour A; Hindré T; Haras D; Le Pennec JP FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664 [TBL] [Abstract][Full Text] [Related]
22. Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. McClerren AL; Cooper LE; Quan C; Thomas PM; Kelleher NL; van der Donk WA Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17243-8. PubMed ID: 17085596 [TBL] [Abstract][Full Text] [Related]
23. Lantibiotics: insight and foresight for new paradigm. Nagao J; Asaduzzaman SM; Aso Y; Okuda K; Nakayama J; Sonomoto K J Biosci Bioeng; 2006 Sep; 102(3):139-49. PubMed ID: 17046525 [TBL] [Abstract][Full Text] [Related]
24. Biosynthesis of paenibacillin, a lantibiotic with N-terminal acetylation, by Paenibacillus polymyxa. Huang E; Yousef AE Microbiol Res; 2015 Dec; 181():15-21. PubMed ID: 26640048 [TBL] [Abstract][Full Text] [Related]
26. Biosynthesis of aminovinyl-cysteine-containing peptides and its application in the production of potential drug candidates. Sit CS; Yoganathan S; Vederas JC Acc Chem Res; 2011 Apr; 44(4):261-8. PubMed ID: 21366289 [TBL] [Abstract][Full Text] [Related]
27. Deuterium labeled peptides give insights into the directionality of class III lantibiotic synthetase LabKC. Krawczyk B; Ensle P; Müller WM; Süssmuth RD J Am Chem Soc; 2012 Jun; 134(24):9922-5. PubMed ID: 22687055 [TBL] [Abstract][Full Text] [Related]
28. The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics. Escano J; Stauffer B; Brennan J; Bullock M; Smith L Microbiologyopen; 2014 Dec; 3(6):961-72. PubMed ID: 25400246 [TBL] [Abstract][Full Text] [Related]
29. Roseocin, a novel two-component lantibiotic from an actinomycete. Singh M; Chaudhary S; Sareen D Mol Microbiol; 2020 Feb; 113(2):326-337. PubMed ID: 31696567 [TBL] [Abstract][Full Text] [Related]
30. Investigation of the substrate specificity of lacticin 481 synthetase by using nonproteinogenic amino acids. Levengood MR; Kerwood CC; Chatterjee C; van der Donk WA Chembiochem; 2009 Mar; 10(5):911-9. PubMed ID: 19222036 [TBL] [Abstract][Full Text] [Related]
31. Characterization of new class III lantibiotics--erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing. Völler GH; Krawczyk JM; Pesic A; Krawczyk B; Nachtigall J; Süssmuth RD Chembiochem; 2012 May; 13(8):1174-83. PubMed ID: 22556031 [TBL] [Abstract][Full Text] [Related]
32. An overview of lantibiotic biosynthetic machinery promiscuity and its impact on antimicrobial discovery. Sandiford SK Expert Opin Drug Discov; 2020 Mar; 15(3):373-382. PubMed ID: 31941374 [No Abstract] [Full Text] [Related]
33. Synergistic binding of the leader and core peptides by the lantibiotic synthetase HalM2. Thibodeaux GN; McClerren AL; Ma Y; Gancayco MR; van der Donk WA ACS Chem Biol; 2015 Apr; 10(4):970-7. PubMed ID: 25619528 [TBL] [Abstract][Full Text] [Related]
34. Sequence-based analysis and prediction of lantibiotics: A machine learning approach. Poorinmohammad N; Hamedi J; Moghaddam MHAM Comput Biol Chem; 2018 Dec; 77():199-206. PubMed ID: 30342319 [TBL] [Abstract][Full Text] [Related]
35. A glycosylated, labionin-containing lanthipeptide with marked antinociceptive activity. Iorio M; Sasso O; Maffioli SI; Bertorelli R; Monciardini P; Sosio M; Bonezzi F; Summa M; Brunati C; Bordoni R; Corti G; Tarozzo G; Piomelli D; Reggiani A; Donadio S ACS Chem Biol; 2014 Feb; 9(2):398-404. PubMed ID: 24191663 [TBL] [Abstract][Full Text] [Related]
36. The lantibiotic mersacidin is an autoinducing peptide. Schmitz S; Hoffmann A; Szekat C; Rudd B; Bierbaum G Appl Environ Microbiol; 2006 Nov; 72(11):7270-7. PubMed ID: 16980420 [TBL] [Abstract][Full Text] [Related]
37. Designing and producing modified, new-to-nature peptides with antimicrobial activity by use of a combination of various lantibiotic modification enzymes. van Heel AJ; Mu D; Montalbán-López M; Hendriks D; Kuipers OP ACS Synth Biol; 2013 Jul; 2(7):397-404. PubMed ID: 23654279 [TBL] [Abstract][Full Text] [Related]
38. CerR, a Single-Domain Regulatory Protein of the LuxR Family, Promotes Cerecidin Production and Immunity in Bacillus cereus. Zhang L; Teng K; Wang J; Zhang Z; Zhang J; Sun S; Li L; Yang X; Zhong J Appl Environ Microbiol; 2018 Mar; 84(5):. PubMed ID: 29247062 [TBL] [Abstract][Full Text] [Related]
39. Heterologous expression, biosynthesis, and mutagenesis of type II lantibiotics from Bacillus licheniformis in Escherichia coli. Caetano T; Krawczyk JM; Mösker E; Süssmuth RD; Mendo S Chem Biol; 2011 Jan; 18(1):90-100. PubMed ID: 21276942 [TBL] [Abstract][Full Text] [Related]
40. Genetics of subtilin and nisin biosyntheses: biosynthesis of lantibiotics. Entian KD; de Vos WM Antonie Van Leeuwenhoek; 1996 Feb; 69(2):109-17. PubMed ID: 8775971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]